Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor
The hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL and is an important therapeutic target for treating cardiovascular disease. Abundance of the LDLR is subject to both transcriptional and nontranscriptional control. Here, we highlight a new post-tra...
Uloženo v:
| Vydáno v: | Current opinion in lipidology Ročník 23; číslo 3; s. 213 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.06.2012
|
| Témata: | |
| ISSN: | 1473-6535, 1473-6535 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL and is an important therapeutic target for treating cardiovascular disease. Abundance of the LDLR is subject to both transcriptional and nontranscriptional control. Here, we highlight a new post-transcriptional mechanism for controlling LDLR function via ubiquitination of the receptor by the E3-ubiquitin ligase inducible degrader of the LDLR (IDOL).
IDOL is a recently identified transcriptional target of the liver X receptors. Acting as an E3-ubiquitin ligase IDOL promotes ubiquitination of the LDLR, thereby marking it for lysosomal degradation. The determinants required for degradation of the LDLR by IDOL have been largely identified. IDOL also targets two related lipoprotein receptors, the very low-density lipoprotein receptor and apolipoprotein E receptor 2. Despite several similarities, the IDOL, and PCSK9 pathways for controlling LDLR abundance seem independent of each other. Genome-wide association studies have recently identified IDOL as a locus influencing variability in circulating levels of LDL, thereby highlighting the possible role of IDOL in human lipoprotein metabolism.
Transcriptional induction of IDOL by liver X receptor defines a new post-transcriptional pathway for controlling LDLR abundance and LDL uptake independent of sterol regulatory element binding proteins. Targeting IDOL activity may offer a novel therapeutic approach complementary to statins for treating cardiovascular disease. |
|---|---|
| AbstractList | The hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL and is an important therapeutic target for treating cardiovascular disease. Abundance of the LDLR is subject to both transcriptional and nontranscriptional control. Here, we highlight a new post-transcriptional mechanism for controlling LDLR function via ubiquitination of the receptor by the E3-ubiquitin ligase inducible degrader of the LDLR (IDOL).PURPOSE OF REVIEWThe hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL and is an important therapeutic target for treating cardiovascular disease. Abundance of the LDLR is subject to both transcriptional and nontranscriptional control. Here, we highlight a new post-transcriptional mechanism for controlling LDLR function via ubiquitination of the receptor by the E3-ubiquitin ligase inducible degrader of the LDLR (IDOL).IDOL is a recently identified transcriptional target of the liver X receptors. Acting as an E3-ubiquitin ligase IDOL promotes ubiquitination of the LDLR, thereby marking it for lysosomal degradation. The determinants required for degradation of the LDLR by IDOL have been largely identified. IDOL also targets two related lipoprotein receptors, the very low-density lipoprotein receptor and apolipoprotein E receptor 2. Despite several similarities, the IDOL, and PCSK9 pathways for controlling LDLR abundance seem independent of each other. Genome-wide association studies have recently identified IDOL as a locus influencing variability in circulating levels of LDL, thereby highlighting the possible role of IDOL in human lipoprotein metabolism.RECENT FINDINGSIDOL is a recently identified transcriptional target of the liver X receptors. Acting as an E3-ubiquitin ligase IDOL promotes ubiquitination of the LDLR, thereby marking it for lysosomal degradation. The determinants required for degradation of the LDLR by IDOL have been largely identified. IDOL also targets two related lipoprotein receptors, the very low-density lipoprotein receptor and apolipoprotein E receptor 2. Despite several similarities, the IDOL, and PCSK9 pathways for controlling LDLR abundance seem independent of each other. Genome-wide association studies have recently identified IDOL as a locus influencing variability in circulating levels of LDL, thereby highlighting the possible role of IDOL in human lipoprotein metabolism.Transcriptional induction of IDOL by liver X receptor defines a new post-transcriptional pathway for controlling LDLR abundance and LDL uptake independent of sterol regulatory element binding proteins. Targeting IDOL activity may offer a novel therapeutic approach complementary to statins for treating cardiovascular disease.SUMMARYTranscriptional induction of IDOL by liver X receptor defines a new post-transcriptional pathway for controlling LDLR abundance and LDL uptake independent of sterol regulatory element binding proteins. Targeting IDOL activity may offer a novel therapeutic approach complementary to statins for treating cardiovascular disease. The hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL and is an important therapeutic target for treating cardiovascular disease. Abundance of the LDLR is subject to both transcriptional and nontranscriptional control. Here, we highlight a new post-transcriptional mechanism for controlling LDLR function via ubiquitination of the receptor by the E3-ubiquitin ligase inducible degrader of the LDLR (IDOL). IDOL is a recently identified transcriptional target of the liver X receptors. Acting as an E3-ubiquitin ligase IDOL promotes ubiquitination of the LDLR, thereby marking it for lysosomal degradation. The determinants required for degradation of the LDLR by IDOL have been largely identified. IDOL also targets two related lipoprotein receptors, the very low-density lipoprotein receptor and apolipoprotein E receptor 2. Despite several similarities, the IDOL, and PCSK9 pathways for controlling LDLR abundance seem independent of each other. Genome-wide association studies have recently identified IDOL as a locus influencing variability in circulating levels of LDL, thereby highlighting the possible role of IDOL in human lipoprotein metabolism. Transcriptional induction of IDOL by liver X receptor defines a new post-transcriptional pathway for controlling LDLR abundance and LDL uptake independent of sterol regulatory element binding proteins. Targeting IDOL activity may offer a novel therapeutic approach complementary to statins for treating cardiovascular disease. |
| Author | Sorrentino, Vincenzo Zelcer, Noam |
| Author_xml | – sequence: 1 givenname: Vincenzo surname: Sorrentino fullname: Sorrentino, Vincenzo organization: Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands – sequence: 2 givenname: Noam surname: Zelcer fullname: Zelcer, Noam |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22510808$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkMlOwzAURS1URAf4A4SyZJPiIYnjJarKIBWVBawjJ3kuRq6d2o5Qf4JvJhEgsWD1hnt09d6do4l1FhC6JHhJsOA3T9vNEteYMGC0ZDmjIuMnaEYyztIiZ_nkTz9F8xDeMSZUYH6GppTmBJe4nKHPZxdiGr20ofG6i9pZaRIPu97IcUicSozuXOddBG0HpYEuOh-S-pjEN0jWLO1rfeh1HFSjdzJAom3bN7o2kLSw87IFP9qMtHEfaQs26Hj81_YcnSppAlz81AV6vVu_rB7Szfb-cXW7SZuMlGUKhZCgpGoUCE5xoYgqCOVlPQSCFcPDdvg6V5xhVYMYKS5AtIw1JQZM6QJdf_sOBxx6CLHa69CAMdKC60NFhlx5QTPBBvTqB-3rPbRV5_Ve-mP1myH9Ah1oemo |
| CitedBy_id | crossref_primary_10_1016_j_jlr_2024_100539 crossref_primary_10_1016_j_tibs_2014_08_008 crossref_primary_10_1128_MCB_00890_15 crossref_primary_10_1016_j_toxicon_2020_12_011 crossref_primary_10_1016_j_phrs_2013_12_002 crossref_primary_10_1113_EP086478 crossref_primary_10_1016_j_jlr_2023_100380 crossref_primary_10_3390_molecules24030493 crossref_primary_10_3892_etm_2025_12796 crossref_primary_10_1371_journal_pone_0172721 crossref_primary_10_1530_EC_22_0019 crossref_primary_10_1097_MOL_0000000000000593 crossref_primary_10_1371_journal_pone_0225356 crossref_primary_10_1016_j_biopha_2015_12_014 crossref_primary_10_1016_j_apsb_2025_05_015 crossref_primary_10_1016_j_phrs_2020_105205 crossref_primary_10_4330_wjc_v12_i7_303 crossref_primary_10_1161_ATVBAHA_118_311168 crossref_primary_10_1016_j_bmc_2022_116856 crossref_primary_10_1016_j_jlr_2022_100325 crossref_primary_10_2217_pgs_12_107 crossref_primary_10_1097_MOL_0000000000000038 crossref_primary_10_1016_j_tcb_2023_09_001 crossref_primary_10_1097_MOL_0000000000000411 crossref_primary_10_1016_j_biopha_2018_08_145 crossref_primary_10_1159_000540898 crossref_primary_10_1016_j_virol_2013_04_003 crossref_primary_10_1038_s41598_020_76224_w crossref_primary_10_1074_jbc_RA120_014349 crossref_primary_10_1097_MOL_0b013e32835cb4f6 crossref_primary_10_1161_ATVBAHA_116_308434 crossref_primary_10_1186_1476_511X_11_121 crossref_primary_10_3389_fimmu_2025_1554311 crossref_primary_10_1016_j_atherosclerosis_2018_12_008 crossref_primary_10_1242_jcs_128132 crossref_primary_10_1161_ATVBAHA_118_312002 crossref_primary_10_1161_ATVBAHA_119_312589 crossref_primary_10_1038_s42003_025_08200_x crossref_primary_10_1161_ATVBAHA_113_301517 crossref_primary_10_1093_eurheartj_ehs472 crossref_primary_10_1161_CIRCRESAHA_115_307298 crossref_primary_10_36290_far_2017_035 crossref_primary_10_1194_jlr_M037713 crossref_primary_10_1016_j_atherosclerosis_2016_09_001 crossref_primary_10_3390_antiox12020477 crossref_primary_10_1074_jbc_M115_698688 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/MOL.0b013e3283532947 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1473-6535 |
| ExternalDocumentID | 22510808 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .-D .GJ .Z2 01R 0R~ 1J1 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ 8L- AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABVCZ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFO ACGFS ACIJW ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFUWQ AGINI AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BOYCO BQLVK BS7 C45 CAG CGR COF CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C N9A NPM N~7 N~B N~M O9- OAG OAH OBC OBS OCUKA ODA OEB OL1 OLC OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XJT XXN XYM YFH ZFV ZZMQN 7X8 ABPXF ACBKD ADKSD |
| ID | FETCH-LOGICAL-c4188-e69aefafcfe97206f1f61278b0b00f30e975355f730fbe9fe9779e9d33c80e022 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 52 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000303939900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1473-6535 |
| IngestDate | Sun Nov 09 10:11:59 EST 2025 Thu Apr 03 06:57:17 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4188-e69aefafcfe97206f1f61278b0b00f30e975355f730fbe9fe9779e9d33c80e022 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 22510808 |
| PQID | 1013762493 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1013762493 pubmed_primary_22510808 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-Jun 20120601 |
| PublicationDateYYYYMMDD | 2012-06-01 |
| PublicationDate_xml | – month: 06 year: 2012 text: 2012-Jun |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Current opinion in lipidology |
| PublicationTitleAlternate | Curr Opin Lipidol |
| PublicationYear | 2012 |
| SSID | ssj0012907 |
| Score | 2.2553322 |
| SecondaryResourceType | review_article |
| Snippet | The hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL and is an important therapeutic target for treating... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 213 |
| SubjectTerms | Animals Humans Lipoproteins, LDL - metabolism Low Density Lipoprotein Receptor-Related Protein-1 - metabolism Proteolysis Receptors, LDL - genetics Receptors, LDL - metabolism Transcription, Genetic Ubiquitin-Protein Ligases - genetics Ubiquitin-Protein Ligases - metabolism |
| Title | Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22510808 https://www.proquest.com/docview/1013762493 |
| Volume | 23 |
| WOSCitedRecordID | wos000303939900008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--3w8iiLdgu2mb5iQiigd39aCyt6VJJ1JY230q-yf8zc70gRcFwUtLSRpKJzPzzSMzjJ2lVilnlBUhRJ5AjW9FbJ0RiYbAaM-GUPo7Xu5VpxN3u_qxdriN67TKRiaWgjotLPnIkbt95AU0FuTlYCioaxRFV-sWGvNsUSKUoZQu1f2OIrR0eVzaD5QUUSjD5uicVhfth_vGB0gVx2RLB-p3kFkqm9u1_37mOlutYSa_qvbFBpuDfJNtXeVoYr_N-DkvEz9Lj_omW27X8fUt9km9e8WE9FcjTXCVUdWvHh944Xg_GxRldYcsxxHKiilGY25mHKEkv5FiarLhNJvgaD97RR3J0eqf2sz0gadUmSKFES1Ds_vFh0gpg34y-3HZbfZ8e_N0fSfqjg3CBj6yHEQ6AZc460Crlhc53yGCUrHBX-056QEd4w1Dh2LFGdA0S2nQqZQ29gDhxA5byIsc9hgP0DKVVD_Oj-IglEmiQ2PQtgGjJN69fXbaEKCHHEFhjiSHYjrufZNgn-1WVOwNqtIdPZRelFQZH_zh7UO2guioVeWFHbFFh_IAjtmSfZ9k49FJudXw2nlsfwE1zuC4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Post-transcriptional+regulation+of+lipoprotein+receptors+by+the+E3-ubiquitin+ligase+inducible+degrader+of+the+low-density+lipoprotein+receptor&rft.jtitle=Current+opinion+in+lipidology&rft.au=Sorrentino%2C+Vincenzo&rft.au=Zelcer%2C+Noam&rft.date=2012-06-01&rft.issn=1473-6535&rft.eissn=1473-6535&rft.volume=23&rft.issue=3&rft.spage=213&rft_id=info:doi/10.1097%2FMOL.0b013e3283532947&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-6535&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-6535&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-6535&client=summon |